NanoViricides Secures $6 Million in Funding to Advance Antiviral Drug Pipeline
NanoViricides has completed a $6 million capital raise to fund development of its broad-spectrum antiviral drug candidates including NV-387 for respiratory infections and NV-HHV-1 for shingles treatment.
NanoViricides, Inc. has successfully closed a $6 million registered direct offering with a healthcare institutional investor, providing crucial capital to advance the company's antiviral drug development pipeline. The transaction involved the sale of 3,571,429 shares of common stock at $1.68 per share, accompanied by concurrent private placements of Series A and Series B warrants for an equal number of shares.
The funding comes at a critical juncture for the clinical-stage company as it prepares to advance its lead drug candidate, NV-387, into Phase II human clinical trials. NV-387 represents a broad-spectrum antiviral drug being developed for multiple respiratory viral infections including RSV, COVID-19, Long COVID, and influenza, as well as MPOX/Smallpox infections. The company's other advanced candidate, NV-HHV-1, targets shingles treatment, positioning NanoViricides to address significant unmet medical needs in antiviral therapeutics.
According to the company's business model detailed on their corporate website https://www.nanoviricides.com, NanoViricides operates by licensing specialized nanomedicine technology from TheraCour Pharma, Inc. for specific antiviral applications. The company holds exclusive, sub-licensable licenses for developing treatments against numerous viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, and multiple influenza strains. The technology platform enables creation of special purpose nanomaterials designed to combat viral infections through novel mechanisms of action.
The warrant structure accompanying this financing provides additional potential capital infusion opportunities for the company. Series A Warrants carry an exercise price of $1.75 per share and become exercisable after six months, expiring in two years. Series B Warrants feature a $2.00 exercise price with a longer 5.5-year expiration period, offering investors extended participation in the company's growth trajectory. A.G.P./Alliance Global Partners acted as sole placement agent for the transaction.
Net proceeds from the offering are designated for working capital and general corporate purposes, supporting the company's ongoing research and development activities. The capital raise demonstrates continued investor confidence in NanoViricides' platform technology and drug development strategy despite the inherent risks of pharmaceutical development. As stated in their corporate disclosures, the path to successful drug development remains lengthy and capital-intensive, with no guarantee that current candidates will demonstrate sufficient effectiveness and safety for human clinical development.
The company maintains additional information through its newsroom at https://ibn.fm/NNVC, providing investors with ongoing updates about development progress and corporate milestones. This financing strengthens NanoViricides' position in the competitive antiviral drug development landscape, particularly as global health concerns around respiratory viruses and emerging pathogens continue to drive demand for innovative therapeutic solutions.